Quarterly report pursuant to Section 13 or 15(d)

RESTATEMENT (Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements) (Details)

RESTATEMENT (Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Statement of Operations
Amortization and depreciation	$ 451		$ 902	$ 10,878
Total Operating Expense	277,978	288,796	562,443	570,798
Income/(Loss) from continuing operations before income taxes	71,122	93,999	106,546	118,597
Net Income/(Loss)	71,122	52,489	106,546	53,661
Net Income/(Loss) attributable to common stockholders	$ 61,003	$ 42,258	$ 86,081	$ 33,086
Income/(Loss) from continuing operations	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Income/(Loss) per common share - basic and diluted	$ 0.00	$ (0.00)	$ 0.00	$ (0.00)
Statement of Changes in Stockholders' Deficit
Additional Paid in Capital	$ 15,266,697		$ 15,266,697			$ 15,266,718
Accumulated Deficit	(15,949,295)		(15,949,295)			(16,055,841)
Total Stockholders' Deficit	(680,250)	$ (898,404)	(680,250)	$ (898,404)	$ (751,372)	(786,796)	$ (1,176,209)	$ (1,177,381)
Total Liabilities and Stockholders' Deficit	367,925		367,925			$ 393,332
Statement of Cash Flow
Net Income/(Loss)	$ 71,122	52,489	$ 106,546	53,661
As previously reported [Member]
Statement of Operations
Amortization and depreciation		46,676		95,910
Total Operating Expense		335,472		655,830
Income/(Loss) from continuing operations before income taxes		47,323		33,565
Net Income/(Loss)		5,813		(31,371)
Net Income/(Loss) attributable to common stockholders		$ (4,418)		$ (51,946)
Income/(Loss) from continuing operations		$ 0.00		$ 0.00
Income/(Loss) per common share - basic and diluted		$ 0.00		$ 0.00
Statement of Changes in Stockholders' Deficit
Additional Paid in Capital		$ 15,866,718		$ 15,866,718
Accumulated Deficit		(16,252,481)		(16,252,481)
Total Stockholders' Deficit		(383,436)		(383,436)
Total Liabilities and Stockholders' Deficit		753,103		753,103
Statement of Cash Flow
Net Income/(Loss)		5,813		(31,371)
Amortization of ReadyMed software platform				85,032
Supplemental disclosures of non-cash investing and financing activities:
Common stock issued for ReadyMed platform				600,000
Adjustment [Member]
Statement of Operations
Amortization and depreciation		(46,676)		(85,032)
Total Operating Expense		(46,676)		(85,032)
Income/(Loss) from continuing operations before income taxes		46,676		85,032
Net Income/(Loss)		46,676		85,032
Net Income/(Loss) attributable to common stockholders		$ 46,676		$ 85,032
Income/(Loss) from continuing operations		$ 0.00		$ 0.00
Income/(Loss) per common share - basic and diluted		$ 0.00		$ 0.00
Statement of Changes in Stockholders' Deficit
Additional Paid in Capital		$ (600,000)		$ (600,000)
Accumulated Deficit		85,032		85,032
Total Stockholders' Deficit		(514,968)		(514,968)
Total Liabilities and Stockholders' Deficit		(514,968)		(514,968)
Statement of Cash Flow
Net Income/(Loss)		46,676		85,032
Amortization of ReadyMed software platform				(85,032)
Supplemental disclosures of non-cash investing and financing activities:
Common stock issued for ReadyMed platform				(600,000)
As Restated [Member]
Statement of Operations
Amortization and depreciation				10,878
Total Operating Expense		288,796		570,798
Income/(Loss) from continuing operations before income taxes		93,999		118,597
Net Income/(Loss)		52,489		53,661
Net Income/(Loss) attributable to common stockholders		$ 42,258		$ 33,086
Income/(Loss) from continuing operations		$ 0.00		$ 0.00
Income/(Loss) per common share - basic and diluted		$ 0.00		$ 0.00
Statement of Changes in Stockholders' Deficit
Additional Paid in Capital		$ 15,266,718		$ 15,266,718
Accumulated Deficit		(16,167,449)		(16,167,449)
Total Stockholders' Deficit		(898,404)		(898,404)
Total Liabilities and Stockholders' Deficit		238,135		238,135
Statement of Cash Flow
Net Income/(Loss)		$ 52,489		53,661
Supplemental disclosures of non-cash investing and financing activities:
Common stock issued for ReadyMed platform